Fujisawa USA/Medco Settle Adenoscan Lawsuits

28 May 1995

Meantime, the company has announced that Fujisawa USA and Medco Research in the USA have agreed to settle their respective lawsuits relating to the manufacturing and marketing of Adenoscan (adenosine; see page 19). As a result, Fujisawa USA will manufacture and market Adenoscan in the USA and Canada under an exclusive license from Medco.

Fujisawa USA was involved in the development of Adenoscan under an agreement which was concluded in December 1988 between its predecessor and Medco. In May 1993, law suits were filed by both companies concerning marketing and manufacturing rights, which have now been settled.

The two companies also announced that the US Food and Drug Administration has given final clearance for the commercialization of Adenoscan, which is indicated as a coronary vasodilator for use with radioactive thallium imaging in patients unable to exercise adequately.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.